SCH23390 effects on apomorphine-induced responses of nigral dopaminergic neurons

T. C. Napier, B. S. Givens, D. W. Schulz, B. S. Bunney, G. R. Breese, R. B. Mailman

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

SCH23390 is a dopamine antagonist which has a high affinity for D1-like dopaminergic receptors. Receptor binding studies demonstrated significant levels of specific SCH23390 binding within nigral tissue. Therefore, electrophysiological experiments were conducted to determine if this antagonist influenced apomorphine-induced suppressions of unit firing recorded from dopaminergic cells of the substantia nigra zona compacta. Results presented in this report indicate that the autoreceptors located on dendrites and cell bodies of dopamine-containing neurons are not directly acted upon by SCH23390. This conclusion is drawn because: 1) doses of SCH23390 known to block behaviors caused by dopamine agonists were ineffective in blocking rate reductions produced by apomorphine and 2) pretreatment with 0.1 mg/kg of SCH23390 did not change the apomorphine dose-response curve for inhibition of dopaminergic neurons. Consistent with this finding, microinjections of SCH23390 into the zona compacta did not alter apomorphine-induced behaviors which are known to be blocked by haloperidol (a D2-like antagonist) intranigral injections. However, when only the larger apomorphine doses (64 and 128 μg/kg i.v.) are considered, SCH23390 pretreatment did attenuate the maximum response to apomorphine in some nigral cells. Because larger apomorphine concentrations alter striatal acitivity, such results may be reflective of alterations in a subpopulation of nigral neurons which are postsynaptic to neurons containing D1-like receptors and located elsewhere in the brain (e.g., in striatum). Collectively, these results agree with previous studies which suggest that dopamine receptors located on dopamine-containing neurons of the substantia nigra zona compacta are likely not of the D1-type.

Original languageEnglish (US)
Pages (from-to)838-845
Number of pages8
JournalJournal of Pharmacology and Experimental Therapeutics
Volume236
Issue number3
StatePublished - Aug 13 1986

Fingerprint

Apomorphine
Dopaminergic Neurons
Substantia Nigra
Herpes Zoster
Neurons
Corpus Striatum
Autoreceptors
Dopamine Antagonists
Dopamine Agonists
Dopamine Receptors
Microinjections
Haloperidol
Dendrites
SCH 23390
Injections
Brain

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Pharmacology

Cite this

Napier, T. C., Givens, B. S., Schulz, D. W., Bunney, B. S., Breese, G. R., & Mailman, R. B. (1986). SCH23390 effects on apomorphine-induced responses of nigral dopaminergic neurons. Journal of Pharmacology and Experimental Therapeutics, 236(3), 838-845.
Napier, T. C. ; Givens, B. S. ; Schulz, D. W. ; Bunney, B. S. ; Breese, G. R. ; Mailman, R. B. / SCH23390 effects on apomorphine-induced responses of nigral dopaminergic neurons. In: Journal of Pharmacology and Experimental Therapeutics. 1986 ; Vol. 236, No. 3. pp. 838-845.
@article{cddd3c5a1f4d4945b6b5d996bf3252d7,
title = "SCH23390 effects on apomorphine-induced responses of nigral dopaminergic neurons",
abstract = "SCH23390 is a dopamine antagonist which has a high affinity for D1-like dopaminergic receptors. Receptor binding studies demonstrated significant levels of specific SCH23390 binding within nigral tissue. Therefore, electrophysiological experiments were conducted to determine if this antagonist influenced apomorphine-induced suppressions of unit firing recorded from dopaminergic cells of the substantia nigra zona compacta. Results presented in this report indicate that the autoreceptors located on dendrites and cell bodies of dopamine-containing neurons are not directly acted upon by SCH23390. This conclusion is drawn because: 1) doses of SCH23390 known to block behaviors caused by dopamine agonists were ineffective in blocking rate reductions produced by apomorphine and 2) pretreatment with 0.1 mg/kg of SCH23390 did not change the apomorphine dose-response curve for inhibition of dopaminergic neurons. Consistent with this finding, microinjections of SCH23390 into the zona compacta did not alter apomorphine-induced behaviors which are known to be blocked by haloperidol (a D2-like antagonist) intranigral injections. However, when only the larger apomorphine doses (64 and 128 μg/kg i.v.) are considered, SCH23390 pretreatment did attenuate the maximum response to apomorphine in some nigral cells. Because larger apomorphine concentrations alter striatal acitivity, such results may be reflective of alterations in a subpopulation of nigral neurons which are postsynaptic to neurons containing D1-like receptors and located elsewhere in the brain (e.g., in striatum). Collectively, these results agree with previous studies which suggest that dopamine receptors located on dopamine-containing neurons of the substantia nigra zona compacta are likely not of the D1-type.",
author = "Napier, {T. C.} and Givens, {B. S.} and Schulz, {D. W.} and Bunney, {B. S.} and Breese, {G. R.} and Mailman, {R. B.}",
year = "1986",
month = "8",
day = "13",
language = "English (US)",
volume = "236",
pages = "838--845",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "3",

}

Napier, TC, Givens, BS, Schulz, DW, Bunney, BS, Breese, GR & Mailman, RB 1986, 'SCH23390 effects on apomorphine-induced responses of nigral dopaminergic neurons', Journal of Pharmacology and Experimental Therapeutics, vol. 236, no. 3, pp. 838-845.

SCH23390 effects on apomorphine-induced responses of nigral dopaminergic neurons. / Napier, T. C.; Givens, B. S.; Schulz, D. W.; Bunney, B. S.; Breese, G. R.; Mailman, R. B.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 236, No. 3, 13.08.1986, p. 838-845.

Research output: Contribution to journalArticle

TY - JOUR

T1 - SCH23390 effects on apomorphine-induced responses of nigral dopaminergic neurons

AU - Napier, T. C.

AU - Givens, B. S.

AU - Schulz, D. W.

AU - Bunney, B. S.

AU - Breese, G. R.

AU - Mailman, R. B.

PY - 1986/8/13

Y1 - 1986/8/13

N2 - SCH23390 is a dopamine antagonist which has a high affinity for D1-like dopaminergic receptors. Receptor binding studies demonstrated significant levels of specific SCH23390 binding within nigral tissue. Therefore, electrophysiological experiments were conducted to determine if this antagonist influenced apomorphine-induced suppressions of unit firing recorded from dopaminergic cells of the substantia nigra zona compacta. Results presented in this report indicate that the autoreceptors located on dendrites and cell bodies of dopamine-containing neurons are not directly acted upon by SCH23390. This conclusion is drawn because: 1) doses of SCH23390 known to block behaviors caused by dopamine agonists were ineffective in blocking rate reductions produced by apomorphine and 2) pretreatment with 0.1 mg/kg of SCH23390 did not change the apomorphine dose-response curve for inhibition of dopaminergic neurons. Consistent with this finding, microinjections of SCH23390 into the zona compacta did not alter apomorphine-induced behaviors which are known to be blocked by haloperidol (a D2-like antagonist) intranigral injections. However, when only the larger apomorphine doses (64 and 128 μg/kg i.v.) are considered, SCH23390 pretreatment did attenuate the maximum response to apomorphine in some nigral cells. Because larger apomorphine concentrations alter striatal acitivity, such results may be reflective of alterations in a subpopulation of nigral neurons which are postsynaptic to neurons containing D1-like receptors and located elsewhere in the brain (e.g., in striatum). Collectively, these results agree with previous studies which suggest that dopamine receptors located on dopamine-containing neurons of the substantia nigra zona compacta are likely not of the D1-type.

AB - SCH23390 is a dopamine antagonist which has a high affinity for D1-like dopaminergic receptors. Receptor binding studies demonstrated significant levels of specific SCH23390 binding within nigral tissue. Therefore, electrophysiological experiments were conducted to determine if this antagonist influenced apomorphine-induced suppressions of unit firing recorded from dopaminergic cells of the substantia nigra zona compacta. Results presented in this report indicate that the autoreceptors located on dendrites and cell bodies of dopamine-containing neurons are not directly acted upon by SCH23390. This conclusion is drawn because: 1) doses of SCH23390 known to block behaviors caused by dopamine agonists were ineffective in blocking rate reductions produced by apomorphine and 2) pretreatment with 0.1 mg/kg of SCH23390 did not change the apomorphine dose-response curve for inhibition of dopaminergic neurons. Consistent with this finding, microinjections of SCH23390 into the zona compacta did not alter apomorphine-induced behaviors which are known to be blocked by haloperidol (a D2-like antagonist) intranigral injections. However, when only the larger apomorphine doses (64 and 128 μg/kg i.v.) are considered, SCH23390 pretreatment did attenuate the maximum response to apomorphine in some nigral cells. Because larger apomorphine concentrations alter striatal acitivity, such results may be reflective of alterations in a subpopulation of nigral neurons which are postsynaptic to neurons containing D1-like receptors and located elsewhere in the brain (e.g., in striatum). Collectively, these results agree with previous studies which suggest that dopamine receptors located on dopamine-containing neurons of the substantia nigra zona compacta are likely not of the D1-type.

UR - http://www.scopus.com/inward/record.url?scp=0022503306&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022503306&partnerID=8YFLogxK

M3 - Article

C2 - 3512819

AN - SCOPUS:0022503306

VL - 236

SP - 838

EP - 845

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 3

ER -